发明名称 Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events caused by CD3-Specific Binding Domains
摘要 The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
申请公布号 US2014227272(A1) 申请公布日期 2014.08.14
申请号 US201414176091 申请日期 2014.02.08
申请人 AMGEN RESEARCH (MUNICH) GMBH 发明人 Kufer Peter;Nagorsen Dirk;Scheele Juergen;Zugmaier Gerhard;Klinger Matthias;Hoffmann Patrick;Naegele Virginie;Dopfer Elaine-Pashupati
分类号 C07K16/28;G01N33/50;A61K31/65;A61K31/10;A61K39/395;C07K16/18 主分类号 C07K16/28
代理机构 代理人
主权项 1. A compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient.
地址 Munich DE